泽纳斯生物制药
ZBIO
24.84
-0.56
-2.20%
泽纳斯生物制药
US · ZBIO
#2856 按市值排名
上市于 2024
24.84
-0.56
-2.20%
实时 - 追踪5344个代码 - 心跳于7秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例上升了6.5个百分点。
机构持股
- 机构持股比例
- 123.85% +6.52pp
- 机构数量
- 184 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund62.53%
VC/PE Fund24.22%
Public Company18.22%
Hedge Fund14.71%
Private Company4.02%
Individual/Insider1.52%
Government Pension Fund0.13%
主要股东 截至 2026-06-30
FMR
14.59% · 9.51M 股
InnoCare Pharma Limited
10.74% · 7.00M 股
Wellington Management Group
10.07% · 6.57M 股
SR One Capital Management, LP
7.73% · 5.04M 股
New Enterprise Associates, Inc.
6.17% · 4.02M 股
Zebra Aggregator, LP
4.98% · 3.25M 股
Federated Hermes, Inc.
4.78% · 3.12M 股
Xencor, Inc.
4.75% · 3.10M 股
BlackRock
4.12% · 2.69M 股
Longitude Capital Management Co., LLC
4.00% · 2.61M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 49次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| InnoCare Pharma Limited | -- | 10.74% |
| Wellington Management Group | -- | 10.07% |
| Leon Moulder | Chairperson & CEO | 0.80% |
| Hongbo Lu | Director | 0.65% |
| Patricia L. Allen | Director | 0.03% |
| Patrick Gerald Enright | Director | 0.02% |
| Tim Xiao | Director | 0.02% |
| Joseph Farmer | Chief Operating Officer | 0.00% |
| Jennifer Fox | Chief Business Officer & CFO | 0.00% |
| Jason Nunn | Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-31 | Christy Oliger | Independent Director | Other Derivative Acquisition | +37,000 | $31.98 |
| 2026-08-25 | InnoCare Pharma Limited | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-06-14 | Leon Moulder | Chairperson & CEO | Other Derivative Acquisition | +500,000 | $18.71 |
| 2026-06-14 | Patrick Gerald Enright | Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | Jason Nunn | Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | Jennifer Fox | Chief Business Officer & CFO | Other Derivative Acquisition | +125,000 | $18.71 |
| 2026-06-14 | Patricia L. Allen | Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | Joseph Farmer | Chief Operating Officer | Other Derivative Acquisition | +175,000 | $18.71 |
| 2026-06-14 | John Orloff | Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | Hongbo Lu | Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | James Boylan | Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | Lisa von Moltke | Head of Research & Development and Chief Medical Officer | Other Derivative Acquisition | +150,000 | $18.71 |
| 2026-05-17 | Leon Moulder | Chairperson & CEO | Open Market Acquisition | +60,000 | $16.88 |
| 2026-04-28 | Tellus BioVentures, LLC | -- | Open Market Acquisition | +60,000 | $17.62–18.02 |
| 2026-03-30 | Hongbo Lu | Director | Open Market Acquisition | +3,768 | $18.63 |
| 2026-03-30 | Fairmount Funds Management LLC | -- | Private Acquisition | +150,000 | $20.00 |
| 2026-03-30 | Tellus BioVentures, LLC | -- | Open Market Acquisition | +54,000 | $18.23–19.31 |
| 2026-03-30 | Nextbio Capital Management LP | -- | Private Acquisition | +75,000 | $20.00 |
| 2026-02-12 | Patricia L. Allen | Director | Open Market Acquisition | +19,860 | $23.77–26.50 |
| 2026-02-10 | Nextbio Capital Management LP | -- | Open Market Acquisition | +25,985 | $22.50 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:15 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
泽纳斯生物制药 讨论区 0 条评论